Latest news with #KhalidNabilsi
Mid East Info
5 days ago
- Business
- Mid East Info
Fitch upgrades Hikma Pharmaceuticals PLC's long-term issuer default rating to ‘BBB', outlook stable - Middle East Business News and Information
Hikma Pharmaceuticals PLC (Hikma, Company) is pleased to announce that Fitch has upgraded its long-term issuer default rating and the senior unsecured rating on Hikma Finance USA LLC's $500 million notes to 'BBB' from 'BBB-' with a stable outlook. Khalid Nabilsi, CFO of Hikma said: 'I am pleased that now both Fitch and S&P have upgraded Hikma to BBB, reinforcing our investment grade rating. These upgrades are a strong endorsement of our strategic direction, financial discipline, and operational resilience. They underscore Hikma's solid market position across key geographies and reflect confidence in our ability to consistently deliver strong financial results, supported by our diversified business model, robust balance sheet, and prudent capital allocation.' About Hikma: Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch) Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world.
Zawya
5 days ago
- Business
- Zawya
Fitch upgrades Hikma Pharmaceuticals PLC's long-term issuer default rating to ‘BBB', outlook stable
Amman, Jordan – Hikma Pharmaceuticals PLC (Hikma, Company) is pleased to announce that Fitch has upgraded its long-term issuer default rating and the senior unsecured rating on Hikma Finance USA LLC's $500 million notes to 'BBB' from 'BBB-' with a stable outlook. Khalid Nabilsi, CFO of Hikma said: 'I am pleased that now both Fitch and S&P have upgraded Hikma to BBB, reinforcing our investment grade rating. These upgrades are a strong endorsement of our strategic direction, financial discipline, and operational resilience. They underscore Hikma's solid market position across key geographies and reflect confidence in our ability to consistently deliver strong financial results, supported by our diversified business model, robust balance sheet, and prudent capital allocation.' About Hikma Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, MENA and Europe.
Zawya
5 days ago
- Business
- Zawya
Fitch upgrades Hikma Pharmaceuticals PLC's long-term issuer default rating to ‘BBB'
Amman, Jordan – Hikma Pharmaceuticals PLC (Hikma, Company) is pleased to announce that Fitch has upgraded its long-term issuer default rating and the senior unsecured rating on Hikma Finance USA LLC's $500 million notes to 'BBB' from 'BBB-' with a stable outlook. Khalid Nabilsi, CFO of Hikma said: 'I am pleased that now both Fitch and S&P have upgraded Hikma to BBB, reinforcing our investment grade rating. These upgrades are a strong endorsement of our strategic direction, financial discipline, and operational resilience. They underscore Hikma's solid market position across key geographies and reflect confidence in our ability to consistently deliver strong financial results, supported by our diversified business model, robust balance sheet, and prudent capital allocation.' About Hikma Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, MENA and Europe. For more information, please visit: *Source: AETOSWire Contacts: Bedour Mossa Email: bmossa@
Zawya
12-05-2025
- Business
- Zawya
Jordan: S&P upgrades Hikma Pharmaceuticals PLC, senior notes to ‘BBB'
AMMAN — S&P has announced on 8 May that it has raised its long-term issuer credit rating on Hikma Pharmaceuticals PLC (Hikma) and its $500 million notes outstanding due on July 9, 2025, issued out of Hikma Finance USA LLC, to 'BBB' from 'BBB-' with a stable outlook. S&P said its rating action reflects Hikma's good business momentum and ability to maintain healthy growth prospects and stable credit metrics, according to a Hikma statement. CFO of Hikma Khalid Nabilsi said: 'I am pleased that S&P have upgraded Hikma, strengthening our investment grade rating and confirming our solid market position as well as our track record of profitability and cash generation.' © Copyright The Jordan Times. All rights reserved. Provided by SyndiGate Media Inc. (
Jordan Times
11-05-2025
- Business
- Jordan Times
S&P upgrades Hikma Pharmaceuticals PLC, senior notes to ‘BBB'
By JT - May 11,2025 - Last updated at May 11,2025 S&P says its rating action reflects Hikma's good business momentum and ability to maintain healthy growth prospects and stable credit metrics (File photo) AMMAN — S&P has announced on 8 May that it has raised its long-term issuer credit rating on Hikma Pharmaceuticals PLC (Hikma) and its $500 million notes outstanding due on July 9, 2025, issued out of Hikma Finance USA LLC, to 'BBB' from 'BBB-' with a stable outlook. S&P said its rating action reflects Hikma's good business momentum and ability to maintain healthy growth prospects and stable credit metrics, according to a Hikma statement. CFO of Hikma Khalid Nabilsi said: 'I am pleased that S&P have upgraded Hikma, strengthening our investment grade rating and confirming our solid market position as well as our track record of profitability and cash generation.'
